ES549135A0 - Un metodo para oxidar una proteina recombinante totalmente reducida - Google Patents

Un metodo para oxidar una proteina recombinante totalmente reducida

Info

Publication number
ES549135A0
ES549135A0 ES549135A ES549135A ES549135A0 ES 549135 A0 ES549135 A0 ES 549135A0 ES 549135 A ES549135 A ES 549135A ES 549135 A ES549135 A ES 549135A ES 549135 A0 ES549135 A0 ES 549135A0
Authority
ES
Spain
Prior art keywords
sup
sub
oxidizing
recombinant protein
totally reduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES549135A
Other languages
English (en)
Other versions
ES8700271A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24725645&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES549135(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of ES549135A0 publication Critical patent/ES549135A0/es
Publication of ES8700271A1 publication Critical patent/ES8700271A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
ES549135A 1984-12-06 1985-11-21 Un metodo para oxidar una proteina recombinante totalmente reducida Expired ES8700271A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/679,121 US4572798A (en) 1984-12-06 1984-12-06 Method for promoting disulfide bond formation in recombinant proteins

Publications (2)

Publication Number Publication Date
ES549135A0 true ES549135A0 (es) 1986-09-01
ES8700271A1 ES8700271A1 (es) 1986-09-01

Family

ID=24725645

Family Applications (1)

Application Number Title Priority Date Filing Date
ES549135A Expired ES8700271A1 (es) 1984-12-06 1985-11-21 Un metodo para oxidar una proteina recombinante totalmente reducida

Country Status (13)

Country Link
US (1) US4572798A (es)
EP (1) EP0185459B1 (es)
JP (1) JPH0696600B2 (es)
KR (1) KR940003475B1 (es)
AT (1) ATE84540T1 (es)
AU (1) AU594930B2 (es)
BR (1) BR8506101A (es)
CA (1) CA1248300A (es)
DE (1) DE3586987T2 (es)
ES (1) ES8700271A1 (es)
GB (1) GB2168055B (es)
IN (1) IN163025B (es)
ZA (1) ZA859001B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925919A (en) * 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
GB8508340D0 (en) * 1985-03-29 1985-05-09 Creighton T E Production of protein
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US4683293A (en) * 1986-10-20 1987-07-28 Phillips Petroleum Company Purification of pichia produced lipophilic proteins
CA1339757C (en) * 1987-04-16 1998-03-17 Robert F. Halenbeck Production of purified biologically active, bacterially produced recombinant human csf-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
DE3855986T2 (de) * 1987-05-11 1998-02-05 Chiron Corp Prozess zur gewinnung von gereinigtem, oxidiertem, renaturiertem, rekombinantem interleukin-2 aus mikroorganismen
US4801691A (en) * 1987-05-15 1989-01-31 International Minerals & Chemical Corp. Method for removing sodium dodecyl sulfate from sodium dodecyl sulfate solubilized protein solutions
JP2669859B2 (ja) * 1987-08-04 1997-10-29 協和醗酵工業株式会社 タンパク質の再活性化法
US5759815A (en) * 1988-02-11 1998-06-02 Creative Biomolecules, Inc. Production of platelet derived growth factor (PDGF) an muteins thereof
CA1340586C (en) * 1988-09-23 1999-06-08 Cetus Corporation Process for recovering microbially produced interferon-beta
JP2517100B2 (ja) * 1989-03-08 1996-07-24 協和醗酵工業株式会社 ヒト顆粒球コロニ―刺激因子活性を有する蛋白質の精製法
US5204256A (en) * 1989-09-06 1993-04-20 Behringwerke Aktiengesellschaft Process for the purification of plasminogen activator inhibitor 2 (pai-2)
AU6870791A (en) * 1989-10-18 1991-05-16 Creative Biomolecules, Inc. Biosynthetic constructs of tgf-beta
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
WO1992009623A1 (fr) * 1990-11-23 1992-06-11 Roussel-Uclaf PROCEDE DE PREPARATION D'UNE PROTEINE COMPORTANT AU MOINS UN PONT DISULFURE INTRAMOLECULAIRE PAR OXYDATION, A UN pH INFERIEUR A 5,0, DE LA PROTEINE RECOMBINANTE REDUITE CORRESPONDANTE
IT1245063B (it) * 1991-04-12 1994-09-13 Ferruzzi Ricerca & Tec Procedimento per l'ossidazione di carboidrati
US5466781A (en) * 1991-05-24 1995-11-14 Chiron Therapeutics Process for purifying bacterially produced M-CSF
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
US20030171292A1 (en) * 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
EP0672144A1 (en) * 1992-10-20 1995-09-20 Chiron Corporation Interleukin-6 receptor antagonists
JPH08502661A (ja) * 1993-08-04 1996-03-26 チバ−ガイギー アクチェンゲゼルシャフト 高分子量デスルファトヒルジン
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
TW517059B (en) 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
DE19547933A1 (de) * 1995-12-22 1997-06-26 Boehringer Mannheim Gmbh Multimere Formen von IL-16, Verfahren zu ihrer Herstellung und Verwendung
WO1998033810A2 (en) 1997-01-30 1998-08-06 University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by a3-restricted cytotoxic lymphocytes, and uses therefor
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
WO1999003887A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
EP2305804B1 (en) * 1999-01-14 2015-05-06 Bolder Biotechnology, Inc. MonoPEGylated human growth hormone
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1935431A3 (en) 2000-05-15 2008-08-13 Health Research, Inc. Cancer treatments by using a combination of an antibody against her2 and interleukin-2
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
HUP0501111A2 (en) * 2001-10-15 2007-12-28 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor
MXPA06000460A (es) * 2003-07-11 2006-04-07 Schering Ag Polipeptidos humanos, recombinantes, mejorados de interferon-beta-1b.
EP2149585B1 (en) 2003-11-04 2013-08-14 Novartis Vaccines and Diagnostics, Inc. Use of antagonistic anti-CD40 monoclonal antibodies
US20080286279A1 (en) * 2004-03-17 2008-11-20 Chiron Corporation Treatment of Severe Community-Acquired Pneumonia by Administration of Tissue Factor Pathway Inhibitor (Tfpi)
LT3327026T (lt) 2007-07-09 2019-11-11 Genentech Inc Disulfidinio ryšio redukcijos prevencija rekombinantinių polipeptidų gaminimo metu
WO2009045553A1 (en) * 2007-10-05 2009-04-09 Barofold, Inc. High pressure treatment of aggregated interferons
PL2424889T3 (pl) 2009-04-30 2016-01-29 Ablynx Nv Sposób wytwarzania przeciwciał domenowych
MX2011013898A (es) * 2009-06-22 2012-05-22 Amgen Inc Proteínas replegadas que usan un estado de oxido-reduccion quimicamente controlado.
EP2445924B2 (en) 2009-06-25 2023-12-13 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
GB201101794D0 (en) * 2011-02-02 2011-03-16 Fermentas Uab Protein production
EP3049445A4 (en) 2013-09-24 2017-10-25 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
EP3204119B1 (en) 2014-10-09 2021-06-09 Dana-Farber Cancer Institute, Inc. Multiple-variable il-2 dose regimen for treating immune disorders
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3067909A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3775927B1 (en) * 2018-03-28 2024-02-07 Two-Tag Holdings Pty Ltd Methods for measuring relative oxidation levels of a protein
KR20220035333A (ko) 2019-05-20 2022-03-22 팬디온 오퍼레이션스, 인코포레이티드 Madcam 표적 면역관용
US11491205B2 (en) 2020-01-14 2022-11-08 Synthekine, Inc. Biased IL2 muteins methods and compositions
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450103A (en) * 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
JPS5927858A (ja) * 1982-08-05 1984-02-14 Nippon Shinyaku Co Ltd ポリペプチドの製法
US4490289A (en) * 1982-09-16 1984-12-25 Hoffmann-La Roche Inc. Homogeneous human interleukin 2
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
IE56372B1 (en) * 1982-12-22 1991-07-03 Genentech Inc Microbially produced rennet methods for its production and plasmids used for its production
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins

Also Published As

Publication number Publication date
DE3586987D1 (de) 1993-02-25
GB2168055B (en) 1988-12-29
EP0185459B1 (en) 1993-01-13
KR860005015A (ko) 1986-07-16
JPS61140600A (ja) 1986-06-27
KR940003475B1 (ko) 1994-04-22
ES8700271A1 (es) 1986-09-01
CA1248300A (en) 1989-01-03
EP0185459A2 (en) 1986-06-25
ZA859001B (en) 1986-08-27
GB8528017D0 (en) 1985-12-18
IN163025B (es) 1988-07-30
AU594930B2 (en) 1990-03-22
JPH0696600B2 (ja) 1994-11-30
GB2168055A (en) 1986-06-11
US4572798A (en) 1986-02-25
DE3586987T2 (de) 1993-05-13
AU5005285A (en) 1986-06-12
EP0185459A3 (en) 1989-02-08
ATE84540T1 (de) 1993-01-15
BR8506101A (pt) 1986-08-19

Similar Documents

Publication Publication Date Title
ES549135A0 (es) Un metodo para oxidar una proteina recombinante totalmente reducida
US4530787B1 (es)
ES8603271A1 (es) Un metodo de producir una composicion de interleuquina-2
DE3650538T2 (de) Interleukin-4 protein mit bcgf- und tcgf-aktivität gegenüber menschlichen zellen (menschliches interleukin-4)
ES2061434T3 (es) Procedimiento para la activacion de proteinas eucarioticas heterologas que contienen puentes de disulfuro, preparadas mediante tecnologia genetica, despues de su expresion en procariotas.
DE3687763T2 (de) Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns-sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen.
DE68901098D1 (de) Zusammensetzung aus antikoagulantia.
ATE14977T1 (de) Haarlegemittel.
ES552233A0 (es) Un metodo para la solubilizacion y renaturalizacion de proteina somatotropina
CA2019671A1 (en) Oxidative denaturation of protein analytes
MX9203879A (es) Muteina de il-6 con cisteina parcialmente suprimida.
EP0312358A3 (en) Method for promoting intramolecular disulfide bond formation in recombinant proteins contained in a denaturant solution
ATE72582T1 (de) Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
AU2284188A (en) Improved process for recovering microbially produced interferon-beta
FR2576753B1 (fr) Nouvelles compositions pour l'alimentation des animaux
ATE47955T1 (de) Lagerstabile saure naehrmittelsosse, die faserige proteinkomplexe enthaelt.
DE69120315T2 (de) Rekombinante DNA-Expressionsvektoren und DNA-Zusammensetzungen, die Isopenizillin N-Epimerase-Aktivität kodieren
SE8800990D0 (sv) Skin-regenerating cosmetic compositon and process for preparing same
ATE291629T1 (de) Expressionssystem für die sekretion von bioaktivem, menschlichem granulozyt-makrophagem koloniestimulierungsfaktor (gm-csf) und anderen heterologen proteinen aus streptomyces
KR870004142A (ko) 인터로이킨-2 유도체의 제조방법
HUT40903A (en) Method for improving the substance of meat-industrial products by using of additives of cyclodextrin base
ATE15651T1 (de) Verwendung von aminosaeuren als pflanzenwachstums- promotoren und promotor-zusammensetzung.
DE3577988D1 (de) Kautschukmischungen welche furazanoxide und salze von uebergangsmetallen enthalten.
FR2549082B2 (fr) Vecteurs perfectionnes d'expression d'une proteine ayant l'activite de l'antitrypsine-a1 humaine
IT8519171A0 (it) Procedimento per l'ottenimento di grassi animali e farine proteiche da scarti di macelleria, di conceria, da carniccio e simili materiali, per uso zootecnico.